KYMR实时信号 | 通过Getagraph.com最大化利润

购买 107522 min ago

@ $36.93

发出时间: 15 Feb 2024 @ 04:32

回报率: -9.64%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 3.50 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	452 364
平均成交量	638 866
市值	2.05B
EPS	$0 ( 2024-02-22 )
下一个收益日期	( $-0.730 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.24
ATR14	$0.0470 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Baker Bros. Advisors Lp	Buy	32 000	Non-Qualified Stock Option (right to buy)
2024-03-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-03-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-03-28	Baker Bros. Advisors Lp	Buy	7 379 066	Prefunded Warrants
2024-03-14	Booth Bruce	Sell	34 473	Common Stock

INSIDER POWER
44.24
Last 97 transactions
Buy: 2 823 290 \| Sell: 1 008 904

音量相关性

長: -0.44 (neutral)

短: 0.59 (weak)

Signal:(45.053) Neutral

Kymera Therapeutics, Inc. 相关性

10 最正相关
GAIA	0.869
GPP	0.858
LIAN	0.857
GRNQ	0.854
DGRE	0.841
BATRK	0.836
AQMS	0.833
XBIT	0.833
WHLM	0.831
BNIXU	0.83

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kymera Therapeutics, Inc. 相关性 - 货币/商品

-0.62
( weak negative )

-0.55
( weak negative )

0.00
( neutral )

-0.36
( neutral )

-0.43
( neutral )

-0.27
( neutral )

Kymera Therapeutics, Inc. 财务报表

Annual	2023
营收:	$78.59M
毛利润:	$75.03M (95.46 %)
EPS:	$-2.52

FY	2023
营收:	$78.59M
毛利润:	$75.03M (95.46 %)
EPS:	$-2.52

FY	2022
营收:	$46.83M
毛利润:	$43.85M (93.64 %)
EPS:	$-2.82

FY	2021
营收:	$72.83M
毛利润:	$72.83M (100.00 %)
EPS:	$-1.976

Financial Reports:

No articles found.

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

实时更新： Kymera Therapeutics, Inc. [KYMR]

Upcoming Earnings Alert